Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Zanni

Showing results (131-140 of 137) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 137 results.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 6, 2025
Clonal Hematopoiesis and Major Adverse Cardiac Events in People With HIV: Insights From the REPRIEVE TrialLiying Xue, Romit Bhattacharya, Md Mesbah Uddin, et al.
JAMA Cardiology|February 21, 2024
Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical TrialMichael T Lu, Heather Ribaudo, Borek Foldyna, et al.
The New England Journal of Medicine|July 24, 2023
Pitavastatin to Prevent Cardiovascular Disease in HIV InfectionSteven K Grinspoon, Kathleen V Fitch, Markella V Zanni, et al.
The Lancet. HIV|March 30, 2026
Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVEEmma M Kileel, Carlos D Malvestutto, Markella V Zanni, et al.
JACC. Heart Failure|July 16, 2018
The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEFNazir Savji, Wouter C Meijers, Traci M Bartz, et al.
Open Forum Infectious Diseases|October 23, 2023
Biological and Clinical Implications of the Vascular Endothelial Growth Factor Coreceptor Neuropilin-1 in Human Immunodeficiency VirusSamuel R Schnittman, Márton Kolossváry, Gabriele Beck-Engeser, et al.
The Journal of Infectious Diseases|July 10, 2020
Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE TrialTomas G Neilan, Kim-Lien Nguyen, Vlad G Zaha, et al.
Pageof 14

Showing results (131-140 of 137) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 137 results.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 6, 2025
Clonal Hematopoiesis and Major Adverse Cardiac Events in People With HIV: Insights From the REPRIEVE TrialLiying Xue, Romit Bhattacharya, Md Mesbah Uddin, et al.
JAMA Cardiology|February 21, 2024
Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical TrialMichael T Lu, Heather Ribaudo, Borek Foldyna, et al.
The New England Journal of Medicine|July 24, 2023
Pitavastatin to Prevent Cardiovascular Disease in HIV InfectionSteven K Grinspoon, Kathleen V Fitch, Markella V Zanni, et al.
The Lancet. HIV|March 30, 2026
Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVEEmma M Kileel, Carlos D Malvestutto, Markella V Zanni, et al.
JACC. Heart Failure|July 16, 2018
The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEFNazir Savji, Wouter C Meijers, Traci M Bartz, et al.
Open Forum Infectious Diseases|October 23, 2023
Biological and Clinical Implications of the Vascular Endothelial Growth Factor Coreceptor Neuropilin-1 in Human Immunodeficiency VirusSamuel R Schnittman, Márton Kolossváry, Gabriele Beck-Engeser, et al.
The Journal of Infectious Diseases|July 10, 2020
Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE TrialTomas G Neilan, Kim-Lien Nguyen, Vlad G Zaha, et al.
Pageof 14